$3.55
10.25% yesterday
NYSE, Dec 04, 10:17 pm CET
ISIN
CH0499880968
Symbol
ADCT

Adc Therapeutics SA Stock price

$3.54
-0.49 12.16% 1M
+0.20 5.99% 6M
+1.55 77.89% YTD
+1.47 71.01% 1Y
+0.03 0.85% 3Y
-32.31 90.13% 5Y
-26.11 88.06% 10Y
-26.11 88.06% 20Y
NYSE, Closing price Thu, Dec 04 2025
-0.41 10.38%
ISIN
CH0499880968
Symbol
ADCT
Industry

Key metrics

Basic
Market capitalization
$438.5m
Enterprise Value
$659.2m
Net debt
$220.6m
Cash
$234.7m
Shares outstanding
112.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.8 | 5.5
EV/Sales
8.8 | 8.3
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-62.9%
Return on Equity
77.9%
ROCE
-53.8%
ROIC
-332.0%
Debt/Equity
-1.9
Financials (TTM | estimate)
Revenue
$75.2m | $79.2m
EBITDA
$-123.0m | $-169.3m
EBIT
$-122.5m | $-141.3m
Net Income
$-166.9m | $-175.2m
Free Cash Flow
$-132.3m
Growth (TTM | estimate)
Revenue
-39.1% | 11.8%
EBITDA
53.2% | -30.9%
EBIT
53.6% | -8.1%
Net Income
54.5% | -11.0%
Free Cash Flow
2.9%
Margin (TTM | estimate)
Gross
92.7%
EBITDA
-163.5% | -213.8%
EBIT
-162.9%
Net
-222.0% | -221.3%
Free Cash Flow
-175.9%
More
EPS
$-1.5
FCF per Share
$-1.2
Short interest
5.7%
Employees
264
Rev per Employee
$270.0k
Show more

Is Adc Therapeutics SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Adc Therapeutics SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Adc Therapeutics SA forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Adc Therapeutics SA forecast:

Buy
92%
Hold
8%

Financial data from Adc Therapeutics SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
75 75
39% 39%
100%
- Direct Costs 5.47 5.47
23% 23%
7%
70 70
40% 40%
93%
- Selling and Administrative Expenses 79 79
54% 54%
106%
- Research and Development Expense 113 113
46% 46%
150%
-123 -123
53% 53%
-164%
- Depreciation and Amortization -0.44 -0.44
128% 128%
-1%
EBIT (Operating Income) EBIT -123 -123
54% 54%
-163%
Net Profit -167 -167
55% 55%
-222%

In millions USD.

Don't miss a Thing! We will send you all news about Adc Therapeutics SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adc Therapeutics SA Stock News

Neutral
Seeking Alpha
one day ago
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript
Neutral
PRNewsWire
2 days ago
ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 months of follow-up Combination continues to be generally well-tolerated with a manageable safety profile LOTIS-7 trial is on track for complete patient enrollment in 1H 2026; plan to share full data at a medical meeting and submit for publicat...
Neutral
PRNewsWire
2 days ago
Company to host corporate webcast to share updated data on December 3, 2025 LAUSANNE, Switzerland , Dec. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, December 3, 2025, at 8:00 a.m. EST to provide an update o...
More Adc Therapeutics SA News

Company Profile

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its products include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Head office Switzerland
CEO Ameet Mallik
Employees 264
Founded 2011
Website adctherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today